[ad_1]
In a joint statement made by the companies, it was stated that the agency was exposed to a cyberattack by the EMA and that Pfizer and BioNTech were informed that some documents related to the presentation of the candidate vaccine “BNT162b2” were illegally accessed. Kovid-19.
In the statement from Pfizer and BioNTech, it was emphasized that EMA assured the companies that the cyberattack incident would not affect the vaccine approval process. On the other hand, in the statement made by the EMA, responsible for the evaluation and approval of medicines and vaccines in the European Union, it was noted that the agency was exposed to a cyberattack, but no details were given about the attack.
In the statement from the EMA, which is based in Amsterdam, the Netherlands, it was stated that an investigation was launched in close cooperation with the relevant authorities and organizations and that more information will be released later.
THE DECISION WILL BE MADE UNTIL DECEMBER 29
class = “cf”>
Meanwhile, BioNTech and Pfizer applied to EMA on November 30 to obtain a license for the vaccine they developed.
The EMA is expected to make its decision on the use of the vaccine on December 29, while Pfizer and BioNTech’s review of the so-called “BNT162b2” vaccine continues.
On the other hand, while the vaccine developed by Pfizer-BioNTech attracted attention in the vaccine race against Kovid-19, the vaccine began to be administered after its approval in the UK on December 2.
Canada also approved the use of the vaccine during the day. Canada is the second country after England to approve the widespread use of this vaccine.
